{"id":67758,"date":"2026-06-09T21:32:47","date_gmt":"2026-06-09T13:32:47","guid":{"rendered":"https:\/\/flcube.com\/?p=67758"},"modified":"2026-06-09T21:32:48","modified_gmt":"2026-06-09T13:32:48","slug":"nurix-and-roche-forge-2-3-billion-global-collaboration-for-btk-degrader-bexobrutideg-across-oncology-immunology-and-neurology","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67758","title":{"rendered":"Nurix and Roche Forge $2.3 Billion Global Collaboration for BTK Degrader Bexobrutideg Across Oncology, Immunology and Neurology"},"content":{"rendered":"\n

Nurix Therapeutics, Inc.<\/strong> (NASDAQ: NRIX<\/a>) and Roche<\/strong> (SWX: ROP<\/a>, OTCMKTS: RHHBY<\/a>) announced today a comprehensive global collaboration to develop and commercialize bexobrutideg<\/strong>, a potential best-in-class oral degrader of Bruton’s tyrosine kinase (BTK), with potential total payments to Nurix of up to $2.3 billion<\/strong>.<\/p>\n\n\n\n

Partnership Structure<\/h2>\n\n\n\n
Component<\/th>Detail<\/th><\/tr><\/thead>
Upfront Payment<\/strong><\/td>$700 million to Nurix<\/td><\/tr>
Total Potential Value<\/strong><\/td>Up to $2.3 billion (including milestones)<\/td><\/tr>
Development Cost Sharing<\/strong><\/td>Nurix 40% \/ Roche 60%<\/td><\/tr>
U.S. Profit\/Loss Split<\/strong><\/td>50\/50 between parties<\/td><\/tr>
U.S. Commercialization<\/strong><\/td>Co-commercialization across all indications<\/td><\/tr>
Ex-U.S. Commercialization<\/strong><\/td>Roche-led with Nurix receiving royalties (low- to high-teens %)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Therapeutic Development Strategy<\/h2>\n\n\n\n

Malignant Hematology Focus<\/h3>\n\n\n\n